Mechanism of action: Pirfenidone reduces the production of transforming growth factor-beta 1 (TGF-beta 1), which is a profibrotic and proinflammatory cytokine implicated in IPF. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.